Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst

Yong Hoon Cha, Eunae Sandra Cho, Hee Eun Kang, Jaemin Ko, Woong Nam, Hyung Jun Kim, Nam Hee Kim, Hyun Sil Kim, Inho Cha, Jong In Yook

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives Odontogenic keratocyst (OKC), also known as keratocystic odontogenic tumor (KCOT), has clinical significance due to its high incidence as well as high recurrence rate after surgical enucleation. Current clinical management for OCK is entirely dependent on surgical approach. While various genetic alterations, such as PTCH1 mutation and loss of heterozygosity in tumor suppressor genes, have been reported, the molecular background of OKC is not well-understood. Although recent identification of BRAF V600E mutation and subsequent activation of mitogen-activated protein kinase (MAPK) pathway in ameloblastoma and odontogenic tumors provide additional options with targeted therapeutics, the molecular background of OKC is not well understood. Materials and methods In this study, we examined BRAF V600E mutation from paraffin embedded OKC samples by tumor cell enriched microdissection and TA cloning of amplified DNA. We further examined the relationship between BRAF V600E mutation and clinical parameters. Results We found frequent BRAF V600E mutation in OKC (24 of 38 samples, 63.2%). However, BRAF V600E mutational status is not related with clinical indexes such as size, location, and recurrence. In orthokeratinized odontogenic cyst, there is one case of BRAF 600E mutation from 11 samples (9.1%). Conclusion These results indicate that BRAF V600E mutation occurs in OKCs at a high rate and plays an important role in the pathogenesis of OKCs.

Original languageEnglish
Pages (from-to)62-67
Number of pages6
JournalOral Oncology
Volume74
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Odontogenic Cysts
Mutation
Odontogenic Tumors
Ameloblastoma
Recurrence
Microdissection
Loss of Heterozygosity
Mitogen-Activated Protein Kinases
Tumor Suppressor Genes
Paraffin
Organism Cloning
DNA
Incidence

All Science Journal Classification (ASJC) codes

  • Oral Surgery
  • Oncology
  • Cancer Research

Cite this

Cha, Y. H., Cho, E. S., Kang, H. E., Ko, J., Nam, W., Kim, H. J., ... Yook, J. I. (2017). Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. Oral Oncology, 74, 62-67. https://doi.org/10.1016/j.oraloncology.2017.09.016
Cha, Yong Hoon ; Cho, Eunae Sandra ; Kang, Hee Eun ; Ko, Jaemin ; Nam, Woong ; Kim, Hyung Jun ; Kim, Nam Hee ; Kim, Hyun Sil ; Cha, Inho ; Yook, Jong In. / Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. In: Oral Oncology. 2017 ; Vol. 74. pp. 62-67.
@article{69d19e7fe4a34bea90de5f958bca0a4d,
title = "Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst",
abstract = "Objectives Odontogenic keratocyst (OKC), also known as keratocystic odontogenic tumor (KCOT), has clinical significance due to its high incidence as well as high recurrence rate after surgical enucleation. Current clinical management for OCK is entirely dependent on surgical approach. While various genetic alterations, such as PTCH1 mutation and loss of heterozygosity in tumor suppressor genes, have been reported, the molecular background of OKC is not well-understood. Although recent identification of BRAF V600E mutation and subsequent activation of mitogen-activated protein kinase (MAPK) pathway in ameloblastoma and odontogenic tumors provide additional options with targeted therapeutics, the molecular background of OKC is not well understood. Materials and methods In this study, we examined BRAF V600E mutation from paraffin embedded OKC samples by tumor cell enriched microdissection and TA cloning of amplified DNA. We further examined the relationship between BRAF V600E mutation and clinical parameters. Results We found frequent BRAF V600E mutation in OKC (24 of 38 samples, 63.2{\%}). However, BRAF V600E mutational status is not related with clinical indexes such as size, location, and recurrence. In orthokeratinized odontogenic cyst, there is one case of BRAF 600E mutation from 11 samples (9.1{\%}). Conclusion These results indicate that BRAF V600E mutation occurs in OKCs at a high rate and plays an important role in the pathogenesis of OKCs.",
author = "Cha, {Yong Hoon} and Cho, {Eunae Sandra} and Kang, {Hee Eun} and Jaemin Ko and Woong Nam and Kim, {Hyung Jun} and Kim, {Nam Hee} and Kim, {Hyun Sil} and Inho Cha and Yook, {Jong In}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.oraloncology.2017.09.016",
language = "English",
volume = "74",
pages = "62--67",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",

}

Cha, YH, Cho, ES, Kang, HE, Ko, J, Nam, W, Kim, HJ, Kim, NH, Kim, HS, Cha, I & Yook, JI 2017, 'Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst', Oral Oncology, vol. 74, pp. 62-67. https://doi.org/10.1016/j.oraloncology.2017.09.016

Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. / Cha, Yong Hoon; Cho, Eunae Sandra; Kang, Hee Eun; Ko, Jaemin; Nam, Woong; Kim, Hyung Jun; Kim, Nam Hee; Kim, Hyun Sil; Cha, Inho; Yook, Jong In.

In: Oral Oncology, Vol. 74, 01.11.2017, p. 62-67.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst

AU - Cha, Yong Hoon

AU - Cho, Eunae Sandra

AU - Kang, Hee Eun

AU - Ko, Jaemin

AU - Nam, Woong

AU - Kim, Hyung Jun

AU - Kim, Nam Hee

AU - Kim, Hyun Sil

AU - Cha, Inho

AU - Yook, Jong In

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Objectives Odontogenic keratocyst (OKC), also known as keratocystic odontogenic tumor (KCOT), has clinical significance due to its high incidence as well as high recurrence rate after surgical enucleation. Current clinical management for OCK is entirely dependent on surgical approach. While various genetic alterations, such as PTCH1 mutation and loss of heterozygosity in tumor suppressor genes, have been reported, the molecular background of OKC is not well-understood. Although recent identification of BRAF V600E mutation and subsequent activation of mitogen-activated protein kinase (MAPK) pathway in ameloblastoma and odontogenic tumors provide additional options with targeted therapeutics, the molecular background of OKC is not well understood. Materials and methods In this study, we examined BRAF V600E mutation from paraffin embedded OKC samples by tumor cell enriched microdissection and TA cloning of amplified DNA. We further examined the relationship between BRAF V600E mutation and clinical parameters. Results We found frequent BRAF V600E mutation in OKC (24 of 38 samples, 63.2%). However, BRAF V600E mutational status is not related with clinical indexes such as size, location, and recurrence. In orthokeratinized odontogenic cyst, there is one case of BRAF 600E mutation from 11 samples (9.1%). Conclusion These results indicate that BRAF V600E mutation occurs in OKCs at a high rate and plays an important role in the pathogenesis of OKCs.

AB - Objectives Odontogenic keratocyst (OKC), also known as keratocystic odontogenic tumor (KCOT), has clinical significance due to its high incidence as well as high recurrence rate after surgical enucleation. Current clinical management for OCK is entirely dependent on surgical approach. While various genetic alterations, such as PTCH1 mutation and loss of heterozygosity in tumor suppressor genes, have been reported, the molecular background of OKC is not well-understood. Although recent identification of BRAF V600E mutation and subsequent activation of mitogen-activated protein kinase (MAPK) pathway in ameloblastoma and odontogenic tumors provide additional options with targeted therapeutics, the molecular background of OKC is not well understood. Materials and methods In this study, we examined BRAF V600E mutation from paraffin embedded OKC samples by tumor cell enriched microdissection and TA cloning of amplified DNA. We further examined the relationship between BRAF V600E mutation and clinical parameters. Results We found frequent BRAF V600E mutation in OKC (24 of 38 samples, 63.2%). However, BRAF V600E mutational status is not related with clinical indexes such as size, location, and recurrence. In orthokeratinized odontogenic cyst, there is one case of BRAF 600E mutation from 11 samples (9.1%). Conclusion These results indicate that BRAF V600E mutation occurs in OKCs at a high rate and plays an important role in the pathogenesis of OKCs.

UR - http://www.scopus.com/inward/record.url?scp=85029790909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029790909&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2017.09.016

DO - 10.1016/j.oraloncology.2017.09.016

M3 - Article

VL - 74

SP - 62

EP - 67

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

ER -